Chemotherapy Drug Development Labelling 
pharmaphorum
DECEMBER 5, 2022
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
pharmaphorum
JULY 22, 2021
The green light for Pemazyre (pemigatinib) has been hailed by cholangiocarcinoma charity AMMF, which said it was a “major milestone” in the fight against the “Cinderella” cancer, which for years has been overlooked by drug developers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 5, 2021
Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression. Meanwhile, drugs targeting TIM-3, LAG3, VISTA and STING also coming through development.
pharmaphorum
APRIL 23, 2021
After a string of disappointments including the failure of bintrafusp alfa , a drug developed with Germany’s Merck KGaA in lung cancer, any approval is welcome news.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.
European Pharmaceutical Review
DECEMBER 5, 2022
PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. The PSMAfore study. Novartis is evaluating opportunities to investigate Pluvicto in earlier stages of prostate cancer.
LifeProNow
MARCH 27, 2023
President, Global Drug Development and Chief Medical Officer, Novartis. For many of these patients, there are currently no targeted therapeutic options outside of the standard chemotherapy and ET. The risk of recurrence peaks within the first three years after initial diagnosis and continues over decades.
Expert insights. Personalized for you.
59 
Let's personalize your content